Whether naturally occurring or man-made, biological threats pose a severe risk in an increasingly globalized world.
The dual-use nature of biological research, with its most recent advances in biotechnology (‘synthetic biology’, gene editing, nanotechnologies etc.) and the rapid diffusion of knowledge, raise proliferation concerns of biological weapons by non-state actors.
Thus, there is an urgent need to develop measures intended to enhance diagnostic, prophylactic and therapeutic capabilities and capacities to improve the ability of society to combat infectious diseases outbreaks, as well as to alleviate the effects of bioterrorism attacks.
We present here two examples of biotechnology usage for biodefence purposes: (i) plants as biofactories for the rapid production of improved biopharmaceuticals (‘Plant Molecular Farming’), and (ii) plant sequences as immune-modulating agents to enhance the efficacy of genetic vaccines.
These platforms represent two promising (and complementary) approaches for the rapid and low-cost production of countermeasures (diagnostics and vaccine candidates) against emerging, re-emerging and bioterrorism-related infections.
Villani ME, Roggero P, Bitti O et al (2005) Immunomodulation of a plant virus infection by intrabodies selected in vitro from a stable single-framework phage display library. Plant Mol Biol 58:305–316CrossRefGoogle Scholar
Franconi R, Roggero P, Pirazzi P et al (1999) Functional expression in bacteria and in plants of an scFv antibody fragment against tospoviruses. Immunotechnology 4(3–4):189–201CrossRefGoogle Scholar
Franconi R, Venuti A (2006) HPV vaccines in plants: an appetising solution to control infection and associated cancers. In: Campo MS (ed) Papillomavirus research: from natural history to vaccines and beyond. Caister Academic Press, Norfolk, pp 357–372Google Scholar
Franconi R, Di Bonito P, Dibello F et al (2002) Plant-derived Human Papillomavirus 16 E7 oncoprotein induces immune response and specific tumor protection. Cancer Res 62:3654–3658Google Scholar
Giorgi C, Franconi R, Rybicki EP (2010) HPV vaccines in plant. Expert Rev Vaccines 9(8):913–924CrossRefGoogle Scholar
Massa S, Franconi R, Brandi R et al (2007) Anti-cancer activity of plant-produced HPV16 E7 vaccine. Vaccine 25:3018–3021CrossRefGoogle Scholar
Venuti A, Massa S, Mett V et al (2009) An E7-based therapeutic vaccine protects mice against HPV16 associated cancer. Vaccine 27:3395–3397CrossRefGoogle Scholar
Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS) (2012) Possession, use, and transfer of select agents and toxins; biennial review. Final rule Fed Regist 77(194):61083–61115Google Scholar
Liu J, Sun Y, Qi J et al (2010) The membrane protein of severe acute respiratory syndrome coronavirus acts as a dominant immunogen revealed by a clustering region of novel functionally and structurally defined cytotoxic T-lymphocyte epitopes. J Infect Dis 202(8):1171–1180. https://doi.org/10.1086/656315CrossRefGoogle Scholar
Gimenez LG, Rojas A, Mendoza J et al (2009) Development of an enzyme-linked immunosorbent assay-based test with a cocktail of nucleocapsid and spike proteins for detection of severe acute respiratory syndrome-associated coronavirus-specific antibody. Clin Vaccine Immunol 6(2):241–245. https://doi.org/10.1128/CVI.00252-08CrossRefGoogle Scholar
Woo PCY, Lau SKP, Wong BHL et al (2004) Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus. Clin Diagn Lab Immunol 11(4):665–668. https://doi.org/10.1128/CDLI.11.4.665-668.2004Google Scholar
Broderick KE, Humeau LM (2017) Enhanced delivery of DNA or RNA vaccines by electroporation. Methods Mol Biol 1499:193–200CrossRefGoogle Scholar
Trimble CL, Morrow MP, Kraynyak KA et al (2015) Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet 386:2078–2088. https://doi.org/10.1016/S0140-6736(15)00239-1CrossRefGoogle Scholar